



NCI SBIR AND YOUR STATE:

ILLINOIS



Between FY1998 and FY2010, the NCI SBIR Development Center awarded **\$15.5 million** in funding across **14 Phase II SBIR/STTR grants** to small businesses in Illinois. The following economic impact estimates quantify the program's contributions to the state's economy:



\$63.5M

IN TOTAL DIRECT SALES



\$582.2M

IN TOTAL ECONOMIC IMPACT



2.7K

JOBS CREATED



\$21.8M

IN STATE & LOCAL TAXES COLLECTED



8

COMPANIES WITH SALES

**These state-specific figures are derived from the 2018 NCI SBIR/STTR Economic Impact Study analysis, which assessed the impact of Phase II grant awards initiated from FY1998-FY2010 and the economic results of these investments up to 2018. NCI continues to provide SBIR/STTR grant awards in Illinois: between FY1998 and FY2024, the NCI SBIR Development Center distributed \$77.4M in funding across all grants to oncology-focused small businesses in the state.*

Success stories include:

SURGICAL INNOVATION ASSOCIATES, INC.

NCI SBIR awardee Surgical Innovation Associates commercialized the DuraSorb® Monofilament Mesh, a fully resorbable soft tissue support technology that aims to improve healing following post-mastectomy breast reconstruction. Integra LifeSciences acquired the company for \$140 million in December 2022.

METRITRACK, INC.

Metritrack used SBIR funding to develop Breast Volume Navigator™, an ultrasound technology that enhances breast cancer mapping precision from detection to treatment. It received FDA clearance in May 2021.

The NCI SBIR Development Center offers information sessions on funding opportunities and resources for cancer technology startups. If your state is interested in hosting, please reach out to ncisbir@mail.nih.gov.